Patricia Carr - Jazz Pharmaceuticals VP Officer
| J7Z Stock | EUR 118.85 2.00 1.71% |
Insider
Patricia Carr is VP Officer of Jazz Pharmaceuticals plc
| Age | 52 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Patricia Carr Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patricia Carr against Jazz Pharmaceuticals stock is an integral part of due diligence when investing in Jazz Pharmaceuticals. Patricia Carr insider activity provides valuable insight into whether Jazz Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Jazz Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jazz Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patricia Carr over six months ago Disposition of 163 shares by Patricia Carr of Jazz Pharmaceuticals at 108.825 subject to Rule 16b-3 |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Renata Brungger | Mercedes Benz Group AG | 62 | |
| Stephen Berenson | Moderna | 58 | |
| Juan Andres | Moderna | 58 | |
| Karsten Knudsen | Novo Nordisk AS | 52 | |
| Sean Marett | BioNTech SE | 58 | |
| Monique Carter | Novo Nordisk AS | 50 | |
| Jerh Collins | Moderna | N/A | |
| Lars Jorgensen | Novo Nordisk AS | 57 | |
| Camilla Sylvest | Novo Nordisk AS | 51 | |
| Michael Boehler | BioNTech SE | N/A | |
| Elizabeth Tallett | Moderna | 70 | |
| Ryan Richardson | BioNTech SE | 44 | |
| Mike Tirozzi | Vertex Pharmaceuticals Incorpor | N/A | |
| Britta Seeger | Mercedes Benz Group AG | 54 | |
| Melissa Moore | Moderna | N/A | |
| Ludovic Helfgott | Novo Nordisk AS | 49 | |
| Ray Jordan | Moderna | N/A | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| Stuart BSc | Vertex Pharmaceuticals Incorpor | 57 | |
| Israel Ruiz | Moderna | 47 | |
| Ozlem MD | BioNTech SE | 56 | |
Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert MD, Ex RD | ||
| Finbar Larkin, VP Operations | ||
| George Eliades, Sr Officer | ||
| Daniel Swisher, President COO | ||
| Patricia Carr, VP Officer | ||
| Heidi Manna, VP Officer | ||
| Neena JD, Ex Officer | ||
| Renee Gala, Ex CFO | ||
| Andrea Flynn, VP Relations | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.